Vanda Pharmaceuticals (VNDA) Earnings Date & Reports

Key Takeaways

• Total net product sales of $50.5 million fell 4% year over year and came in below the consensus estimate of roughly $61.9 million.
• Net loss widened to $62.5 million from $27.2 million a year earlier, producing a diluted loss per share (EPS) of $1.04 versus a consensus estimate of about -$0.58.
• Fanapt net product sales rose 23% to $36.0 million, while HETLIOZ sales dropped 66% to $5.6 million on generic competition and shipment timing.
• Vanda reiterated its full-year 2026 revenue guidance of $240 million to $290 million.
• Cash, cash equivalents, and marketable securities totaled $170 million, which management expects to fund operations through at least the end of 2027.

Earnings Context and Why It Matters

Vanda Pharmaceuticals is a biopharmaceutical company focused on therapies for central nervous system disorders and rare diseases. This report matters because it tests whether the rapid growth of Fanapt (iloperidone), recently expanded into bipolar I disorder, can offset the steep decline of HETLIOZ (tasimelteon) as it faces generic competition. At the same time, the company is funding several late-stage clinical programs and the early launches of NEREUS and BYSANTI, pushing operating expenses sharply higher. Investors are closely watching whether new product momentum arrives fast enough to absorb the HETLIOZ erosion and stem a widening bottom-line loss.

Reported Results

Vanda reported total net product sales of $50.5 million for the second quarter ended June 30, 2026, a 4% decrease from $52.6 million in the prior-year period and below the consensus estimate of approximately $61.9 million. The diluted net loss per share was $1.04, compared with a loss of $0.46 a year earlier and a consensus estimate of about -$0.58, meaning results missed expectations on both the top and bottom lines.

Performance was highly uneven across the portfolio. Fanapt net product sales increased 23% year over year to $36.0 million, driven by volume, with total prescriptions (TRx) up 31% and new-to-brand prescriptions (NBRx) up 32% versus Q2 2025. HETLIOZ net product sales fell 66% to $5.6 million, reflecting continued U.S. generic competition as well as shipment timing; roughly $7 million in HETLIOZ orders shipped on June 29 arrived July 1 and will be recognized in Q3. PONVORY sales rose 12% to $7.9 million, while newly launched NEREUS contributed $1.0 million following its May 2026 commercial debut.

The net loss widened to $62.5 million from $27.2 million, as operating expenses climbed to $114.3 million from $91.1 million, reflecting higher research and development spending and selling, general, and administrative costs tied to launch preparations. For the first six months of 2026, revenue was essentially flat at $102.2 million, while the net loss reached $111.1 million, up from $56.7 million a year earlier.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking biopharmaceutical names like Vanda Pharmaceuticals, the AI Screener offers a structured way to surface relevant opportunities across the sector.

Market Reaction and Investor Sentiment

Investor sentiment around Vanda's quarterly earnings has been shaped by the tension between a growing psychiatry franchise and widening losses. The second-quarter miss on both revenue and EPS — compounded by a net loss more than double the year-ago figure — reinforced concerns about heavy spending ahead of multiple product launches. At the same time, the 23% growth in Fanapt and the reiterated full-year guidance provided a counterweight, signaling that management still expects meaningful commercial expansion in the second half of 2026.

Key risk factors include the ongoing generic erosion of HETLIOZ, the timing of revenue recognition from late-quarter shipments, and execution uncertainty around the NEREUS and BYSANTI launches. The disclosure that 2026 cash burn is likely to exceed 2025 levels has also kept investors focused on the company's $170 million cash position and its path toward moderating expenses.

Forward Outlook and Key Factors to Monitor

Vanda reiterated full-year 2026 revenue guidance of $240 million to $290 million, which includes combined Fanapt and BYSANTI net product sales of $150 million to $170 million and NEREUS sales of $10 million to $30 million. The successful second-half launch of BYSANTI (milsaperidone), approved in Q1 2026 for bipolar I disorder and schizophrenia, is a central near-term catalyst, along with the ramp of NEREUS promotion beyond its initial direct-to-consumer portal.

Investors should also monitor several regulatory and clinical milestones. The U.S. Food and Drug Administration (FDA) is reviewing the Biologics License Application (BLA) for Quimilza (imsidolimab) in generalized pustular psoriasis, with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026. Multiple Phase III readouts are expected by year-end or early 2027, including NEREUS in GLP-1 (glucagon-like peptide-1) induced vomiting, VQW-765 in social anxiety disorder, and HETLIOZ in delayed sleep phase disorder (DSPD).

On the financial side, management expects operating expenses to begin moderating late in 2026 and to decline more substantially in 2027 as late-stage programs and commercial supply manufacturing conclude. The pace of that cost reduction, combined with the trajectory of Fanapt, BYSANTI, and NEREUS revenue, will be central to whether the company can narrow its losses while funding its pipeline through at least the end of 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations